Take Care opens four clinics in Pittsburgh area; plans for fifth by year’s end
PITTSBURGH, Pa. Take Care Health Systems, which is owned by Walgreens, has expanded its presence in Pennsylvania with new retail-based health clinics in the Philadelphia area and Pittsburgh.
The company has opened the doors of four new clinics in the Pittsburgh area.
A fifth new clinic is slated to open in Pittsburgh in late December. These openings are in addition to eight existing Pittsburgh locations. There are now 15 clinics statewide.
As previously reported by Drug Store News, the company also recently launched seven Take Care Clinics in the Philadelphia area, including Pennsylvania, Delaware and New Jersey.
“The expansion in Pennsylvania underscores our commitment to creating better access to health care in the state. Pittsburgh residents have embraced this high-quality, affordable and convenient health care since September 2006 when the first Take Care Clinic opened locally,” said Peter Miller, Take Care Health Systems president and chief executive officer. “We are thrilled to have locations in the Pittsburgh and Philadelphia areas, offering quality health care built around patients’ needs.”
There are currently 304 Take Care Clinics in operation.
FDA grants orphan drug status to two non-Hodgkin’s lymphoma drugs
AMSTERDAM, Netherlands The Food and Drug Administration has granted orphan drug designations to Kiadis Pharma’s drug Reviroc for two types of non-Hodgkin’s lymphoma, Kiadis announced Monday.
The FDA granted one designation for diffuse large B-cell lymphoma and one for follicular lymphoma. The drug is under development for the elimination of cancer cells from an autologous graft in bone marrow transplants for end-stage blood cancer patients.
“This is an important strategic milestone in the development of Reviroc, and we are very pleased with the orphan drug designations received from the FDA,” Kiadis chief executive officer Manja Bouman said in a statement.
The FDA gives orphan drug designations to drugs developed for treating diseases and conditions affecting fewer than 200,000 people in the United States. The designation allows for accelerated review, tax benefits, exemption from user fees and a seven-year period of market exclusivity in the U.S. after regulatory approval.
FDA approves Boostrix vaccine for use in adults
NEW YORK The Food and Drug Administration has approved a booster vaccine for use in adults, manufacturer GlaxoSmithKline announced Monday.
GSK developed the vaccine, Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed), for use in patients aged 10 to 18 as a protection against tetanus, diphtheria and whooping cough; the FDA’s new approval allows for its use in patients aged 19 to 64 as well.
The new approval follows two clinical trials of 3,000 adult patients.
Sanofi-Aventis makes a similar vaccine, Adacel, for use in patients aged 11 to 64.